Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous FMT for Acute GI GVHD
NCT03492502Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous fecal microbiota transplantation, sponsored by Rambam Health Care Campus. Primary endpoint: Severe Adverse Events at 7 days. Planned start Aug 2019; status: withdrawn.
02
Drugs
autologous fecal microbiota transplantation
Beyond the preview
Go deeper on NCT03492502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492502.